<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00036972</url>
  </required_header>
  <id_info>
    <org_study_id>NEOPHARM-IL13PEI-002-R01</org_study_id>
    <secondary_id>MSKCC-01141</secondary_id>
    <secondary_id>CDR0000069345</secondary_id>
    <secondary_id>NCI-G02-2066</secondary_id>
    <nct_id>NCT00036972</nct_id>
  </id_info>
  <brief_title>Immunotoxin Therapy Before and After Surgery in Treating Patients With Recurrent Malignant Glioma</brief_title>
  <official_title>Phase I Study to Assess the Histologic Effect and Safety of Pre-Operative and Post-Operative Infusions of IL13-PE38QQR Cytotoxin in Patients With Recurrent Resectable Supratentorial Malignant Glioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells.&#xD;
      Immunotoxin therapy may be effective in treating malignant glioma.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of immunotoxin therapy before and after&#xD;
      surgery in treating patients who have recurrent malignant glioma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the concentration of interleukin-13 PE38QQR immunotoxin that produces&#xD;
           histologic evidence of toxicity to tumor and the corresponding toxic effects of this&#xD;
           drug when administered via continuous intratumoral infusion prior to second resection in&#xD;
           patients with recurrent resectable supratentorial malignant glioma.&#xD;
&#xD;
        -  Determine the toxic effects of this drug when administered via continuous peritumoral&#xD;
           infusion, at concentrations determined in objective I, after second resection in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine any toxic effects of increasing the duration of continuous peritumoral&#xD;
           infusion of this drug, at concentrations determined in objective II, after second&#xD;
           resection in these patients.&#xD;
&#xD;
        -  Determine the time to progression and survival of patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation, multicenter study.&#xD;
&#xD;
        -  Pre-resection therapy (initial cohorts of patients only): Patients undergo stereotactic&#xD;
           biopsy of brain tumor followed by stereotactic placement of 1 intratumoral catheter on&#xD;
           day 1. Patients with histologically confirmed malignant glioma receive interleukin-13&#xD;
           PE38QQR immunotoxin via continuous intratumoral infusion over 48 hours on days 2 and 3.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of pre-resection interleukin-13 PE38QQR&#xD;
      immunotoxin until the histologically effective concentration (HEC) is reached or maximum&#xD;
      tolerated dose (MTD) is determined. The HEC is defined by pathologic observations. The MTD is&#xD;
      defined as the dose preceding that at which 2 of 6 patients experience dose-limiting&#xD;
      toxicity. After the HEC is reached or MTD is determined, up to 6 additional patients are&#xD;
      enrolled at selected dose levels to study safety and tolerability. Subsequent cohorts of&#xD;
      patients are not treated with a pre-resection infusion.&#xD;
&#xD;
        -  Resection (all patients): Patients undergo maximal resection (en bloc, if feasible)&#xD;
           followed by placement of 2-3 peritumoral catheters (4 days after completion of&#xD;
           pre-resection infusion for the initial cohorts of patients and at study entry for&#xD;
           subsequent cohorts of patients).&#xD;
&#xD;
        -  Post-resection therapy (all patients): Beginning on the second day after resection,&#xD;
           patients receive interleukin-13 PE38QQR immunotoxin via continuous peritumoral infusion&#xD;
           over 96 hours.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of interleukin-13 PE38QQR immunotoxin until&#xD;
      the previously-defined HEC is reached or MTD is determined, whichever occurs first. If&#xD;
      dose-escalation is stopped after HEC is reached, then three additional cohorts of patients&#xD;
      receive escalating durations (5, 6, or 7 days) of post-resection infusion. If dose escalation&#xD;
      is stopped after the MTD is determined, then the duration of post-resection infusion is not&#xD;
      escalated.&#xD;
&#xD;
      Patients are followed every 8 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 25-50 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2001</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">January 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cintredekin besudotox</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed supratentorial malignant glioma (grade 3 or 4)&#xD;
&#xD;
               -  Anaplastic astrocytoma&#xD;
&#xD;
               -  Glioblastoma multiforme&#xD;
&#xD;
               -  Mixed oligoastrocytoma&#xD;
&#xD;
               -  Malignant astrocytoma, not otherwise specified&#xD;
&#xD;
          -  Prior first resection of brain tumor&#xD;
&#xD;
          -  Prior cranial radiotherapy with tumor dose of at least 48 Gy&#xD;
&#xD;
          -  Radiographic evidence of recurrent or progressive supratentorial tumor&#xD;
&#xD;
               -  In patients who have received external beam radiotherapy or localized&#xD;
                  radiotherapy (e.g., gamma-knife or brachytherapy) within the past 12 weeks,&#xD;
                  progression must be confirmed by metabolic imaging (magnetic resonance&#xD;
                  spectroscopy or positron-emission tomography)&#xD;
&#xD;
          -  Must be a candidate for second resection&#xD;
&#xD;
          -  No signs of impending herniation&#xD;
&#xD;
          -  No midline shift greater than 1 cm&#xD;
&#xD;
          -  No multifocal disease or subependymal tumor spread&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 9 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  PT and PTT no greater than upper limit of normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No uncontrolled seizures&#xD;
&#xD;
          -  No other neurologic condition that would interfere with study evaluation&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception during and for 60 days after&#xD;
             study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior cytotoxic therapy (2 weeks for vincristine or 6 weeks for&#xD;
             nitrosoureas)&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Concurrent steroids allowed&#xD;
&#xD;
          -  No tapering of steroids during or immediately after study infusion&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
          -  At least 4 weeks since prior investigational agents&#xD;
&#xD;
          -  At least 2 weeks since prior non-cytotoxic agents&#xD;
&#xD;
          -  No other concurrent antitumor therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lauren E. Abrey, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kunwar S, Prados MD, Chang SM, Berger MS, Lang FF, Piepmeier JM, Sampson JH, Ram Z, Gutin PH, Gibbons RD, Aldape KD, Croteau DJ, Sherman JW, Puri RK; Cintredekin Besudotox Intraparenchymal Study Group. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol. 2007 Mar 1;25(7):837-44.</citation>
    <PMID>17327604</PMID>
  </reference>
  <verification_date>December 2009</verification_date>
  <study_first_submitted>May 13, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 25, 2013</last_update_submitted>
  <last_update_submitted_qc>June 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2013</last_update_posted>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult mixed glioma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

